Extended indication Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement
Therapeutic value No estimate possible yet
Registration phase Registration application pending

Product

Active substance Pegcetacoplan
Domain Cardiovascular diseases
Reason of inclusion Indication extension IND
Main indication Other non-oncological hematological medications
Extended indication Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor
Proprietary name Aspaveli
Manufacturer Sobi
Mechanism of action Complement inhibitor
Route of administration Unknown
Therapeutical formulation Unknown
Budgetting framework Extramural (GVS)

Registration

Registration route Centralised (EMA)
Type of trajectory Normal trajectory
Particularity Unknown
ATMP No
Submission date April 2023
Expected Registration February 2024
Orphan drug Yes
Registration phase Registration application pending

Therapeutic value

Therapeutic value No estimate possible yet

This assessment does not indicate any potential inclusion in the package.

Expected patient volume per year

Patient volume

Market share is generally not included unless otherwise stated.

Expected cost per patient per year

Potential total cost per year

Off label use

Off label use Unknown

Indication extension

Indication extensions Unknown

Other information